{"entity":{"id":"nct05768919","kind":"trial","name":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","aka":[],"tldr":"A phase 1/2 trial of Treatment Period 1 in glioma & glioblastoma, run by SignPath Pharma, Inc., now recruiting.","summary":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas is a phase 1/2 interventional study registered as NCT05768919 by SignPath Pharma, Inc., with 30 participants planned, started 2023-03-03 and due to reach its primary completion in 2026-02. Interventions recorded: Treatment Period 1, Treatment Period 2, Treatment Period 3 and Treatment Period 4a.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05768919","url":"https://clinicaltrials.gov/study/NCT05768919"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05768919","phase":"1/2","setting":"Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas","sponsor":"SignPath Pharma, Inc.","enrolled":30,"outcomes":[]},"route":"/trials/nct05768919/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}